Table 5

Results of POP-Q assessment

Anatomical site in vagina
Timepoint
Oestrogen
N; mean (SD)
No treatment
N; mean (SD)
Mean difference between groups (95% CI)
Aa (anterior wall), cm
 Baselinen=49;n=48;
0.1 (1.9)−0.3 (1.7)
 6 months*n=26;n=29;0.7 (0.1 to 1.3)
−1.7 (2.0)−2.6 (2.0)
Ba (anterior edge), cm
 Baselinen=49;n=48;
0.2 (2.0)0.1 (1.8)
 6 months*n=25;n=29;0.6 (0.0 to 1.2)
−2.0 (2.0)−2.9 (1.9)
C (cervix/cuff), cm
 Baselinen=49;n=48;
−3.7 (2.5)−3.4 (3.4)
 6 months*n=25;n=29;−0.2 (−1.3 to 0.9)
−2.9 (2.8)−2.2 (3.6)
Ap (posterior wall), cm
 Baselinen=49;n=48;
−1.2 (1.5)−1.0 (1.7)
 6 months*n=26;n=29;0.5 (−0.2 to 1.1)
−0.8 (1.7)−1.0 (1.7)
Bp (posterior edge), cm
 Baselinen=49;n=48;
−1.1 (1.6)−1.0 (1.8)
 6 months*n=26;n=29;0.4 (−0.3 to 1.1)
−0.9 (1.8)−1.0 (1.8)
D (posterior fornix), cm
 Baselinen=39;n=40;
−5.3 (1.9)−5.1 (2.6)
 6 months*n=7;n=4;0.7 (−6.2 to 7.5)
−1.3 (1.5)−1.8 (1.9)
Total vaginal length, cm
 Baselinen=49;n=48;
8.5 (1.1)8.0 (1.6)
 6 months†n=26;n=29;0.3 (0.4 to 0.9)
−0.2 (1.3)−0.5 (1.7)
Objective prolapse (any of Aa, Ba, C, Ap, Bp or D >0) at 6 months
N (%)N (%)Relative risk (95% CI)‡
 Failure26-Sep13/290.77 (0.40 to 1.50)
  • *Change from baseline adjusted for baseline; difference <0 indicates better with oestrogen.

  • †Adjusted for baseline length; difference <0 indicates better with oestrogen.

  • ‡<1 indicates less prolapse failures with oestrogen.

  • POP, pelvic organ prolapse; POP-Q, POP quantification system.